logo
Plus   Neg
Share
Email

Peregrine Cites Clinical Data To Highlight Potential Of Bavituximab

Clinical-stage biopharmaceutical company Peregrine Pharmaceuticals Inc (PPHM) Wednesday highlighted positive data from two Phase I investigator-sponsored trials and one preclinical study while evaluating the potential of bavituximab when combined with standard approved therapies in breast, liver and prostate cancers.

The company stated that in a Phase I trial of bavituximab with paclitaxel in five evaluable patients with HER-2 negative metastatic breast cancer, two patients achieved a complete tumor response, one achieved a partial response, and two had progressive disease according to Response Evaluation Criteria In Solid Tumors measurement criteria.

Additionally, the company presented data from a Phase I/II trial investigating bavituximab with sorafenib in patients with advanced hepatocellular carcinoma, in which no dose-limiting toxicities or serious adverse events were observed in the first phase of the trial.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In a signing ceremony for a bill rolling back regulations on small and medium-sized banks, President Donald Trump suggested Thursday he would also consider cutting regulations on larger financial institutions. Trump claimed complex and costly regulations implemented following the 2008 financial crisis... Shares of Hong Kong-listed Samsonite International S.A., the world's biggest luggage maker, tumbled almost 10 percent in Thursday's trading after a short seller issued a report saying that the company suffered from questionable accounting practices and poor corporate governance. Trading in Samsonite's shares were halted after the report was released. In a move likely to add to concerns about the possibility of a global trade war, the Commerce Department has initiated an investigation into whether imports of automobiles and parts threaten to impair U.S. national security. Commerce Secretary Wilbur Ross launched the investigation under Section 232...
Follow RTT